Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 2 Vaccine in Adults and Children.

Authors :: Karron, Ruth A
Herbert, Kristi
Wanionek, Kimberli
Schmidt, Alexander C
Schaap-Nutt, Anne
Collins, Peter L
Buchholz, Ursula J
Source :: Journal of the Pediatric Infectious Diseases Society; Mar2023, Vol. 12 Issue 3, p173-176, 4p
Publication Year :: 2023
Abstract: We conducted a phase I clinical trial of the live-attenuated recombinant human parainfluenza virus type 2 (HPIV2) vaccine candidate rHPIV2-15C/948L/∆1724 sequentially in adults, HPIV2-seropositive children, and HPIV2-seronegative children, the target population for vaccination. rHPIV2-15C/948L/∆1724 was appropriately restricted in replication in adults and HPIV2-seropositive children but was overattenuated for HPIV2-seronegative children. [ABSTRACT FROM AUTHOR]

Subjects :: INFLUENZA prevention
INFLUENZA vaccines
RNA virus infections
IMMUNIZATION
VACCINES
VACCINE effectiveness
RANDOMIZED controlled trials
INTRANASAL administration
PARAMYXOVIRUSES
VIRAL antibodies
RNA viruses
STATISTICAL sampling
EVALUATION
CHILDREN
ADULTS

Full Text Access

Tools